Kala Bio Inc
27F0
Company Profile
Business description
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA’smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Contact
1167 Massachusetts Avenue
ArlingtonMA02476
USAT: +1 781 996-5252
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
Wide moat miner looking to shift focus
Investors cheered an increased dividend but still heavily dependent on iron ore.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,227.50 | 10.30 | 0.11% |
| CAC 40 | 8,361.46 | 44.96 | 0.54% |
| DAX 40 | 24,998.40 | 197.49 | 0.80% |
| Dow JONES (US) | 49,533.19 | 32.26 | 0.07% |
| FTSE 100 | 10,545.22 | 71.53 | 0.68% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,578.38 | 31.71 | 0.14% |
| Nikkei 225 | 57,258.72 | 692.23 | 1.22% |
| NZX 50 Index | 13,247.02 | 215.40 | 1.65% |
| S&P 500 | 6,843.22 | 7.05 | 0.10% |
| S&P/ASX 200 | 8,998.20 | 4.00 | 0.04% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |